Source:http://linkedlifedata.com/resource/pubmed/id/17267204
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2007-2-26
|
pubmed:databankReference | |
pubmed:abstractText |
The SFOP-OS94 randomised multi-centre trial was designed to determine whether preoperative chemotherapy regimen combining high-dose methotrexate courses and etoposide-ifosfamide could improve the proportion of good histologic response (5% viable cells) compared to a regimen based on high-dose methotrexate and doxorubicin, in children/adolescents with localised high-grade limb osteosarcoma. Postoperative chemotherapy was adapted to the histologic response. Overall, 234 patients were randomised between 1994 and 2001. There were 56% good responders in the etoposide-ifosfamide arm versus 39% in the doxorubicin arm (p-value=0.009). With a median follow-up of 77 months, the 5-year event-free survival of the entire population was 62%, slightly greater in the etoposide-ifosfamide arm than in the doxorubicin arm, but the difference was not significant (Hazard Ratio: HR=0.71, 95%CI: 0.5-1.06, p-value=0.09). Five-year overall survival of the entire population was 76%, similar in both arms (HR=0.95, 95%CI: 0.6-1.6, p-value=0.85). Toxicity was manageable with different acute toxicity profiles between treatment arms. No acute toxicity related death was reported. About 43% of the patients in the etoposide-ifosfamide arm were event-free at 3 years without having received any doxorubicin or cisplatin, thus avoiding the risk of long-term cardio- and ototoxicity.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0959-8049
|
pubmed:author |
pubmed-author:BrugièresLaurenceL,
pubmed-author:DupoüyNoëlleN,
pubmed-author:Entz-WerléNatachaN,
pubmed-author:GentetJean-ClaudeJC,
pubmed-author:GuinebretièreJean-MarcJM,
pubmed-author:KalifaChantalC,
pubmed-author:Le DeleyMarie-CécileMC,
pubmed-author:Marec-BérardPerrineP,
pubmed-author:PacquementHélèneH,
pubmed-author:PichonFabienneF,
pubmed-author:SchmittClaudineC,
pubmed-author:Société Française d'Oncologie Pédiatrique (SFOP),
pubmed-author:TaboneMarie-DominiqueMD,
pubmed-author:VanelDanielD
|
pubmed:issnType |
Print
|
pubmed:volume |
43
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
752-61
|
pubmed:dateRevised |
2007-11-20
|
pubmed:meshHeading |
pubmed-meshheading:17267204-Adolescent,
pubmed-meshheading:17267204-Adult,
pubmed-meshheading:17267204-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17267204-Bone Neoplasms,
pubmed-meshheading:17267204-Child,
pubmed-meshheading:17267204-Child, Preschool,
pubmed-meshheading:17267204-Disease-Free Survival,
pubmed-meshheading:17267204-Doxorubicin,
pubmed-meshheading:17267204-Etoposide,
pubmed-meshheading:17267204-Female,
pubmed-meshheading:17267204-Follow-Up Studies,
pubmed-meshheading:17267204-Humans,
pubmed-meshheading:17267204-Ifosfamide,
pubmed-meshheading:17267204-Male,
pubmed-meshheading:17267204-Methotrexate,
pubmed-meshheading:17267204-Osteosarcoma,
pubmed-meshheading:17267204-Preoperative Care
|
pubmed:year |
2007
|
pubmed:articleTitle |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
|
pubmed:affiliation |
Service de Biostatistique et d'Epidémiologie, Institut Gustave-Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France. le_deley@igr.fr
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|